Cyclacel Pharmaceuticals Stock Alpha and Beta Analysis
| CYCC Stock | USD 0.41 0.06 17.14% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Cyclacel Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Cyclacel Pharmaceuticals over a specified time horizon. Remember, high Cyclacel Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Cyclacel Pharmaceuticals' market risk premium analysis include:
Beta 0.58 | Alpha (1.27) | Risk 7.98 | Sharpe Ratio (0.14) | Expected Return (1.15) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Cyclacel |
Cyclacel Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Cyclacel Pharmaceuticals market risk premium is the additional return an investor will receive from holding Cyclacel Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Cyclacel Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Cyclacel Pharmaceuticals' performance over market.| α | -1.27 | β | 0.58 |
Cyclacel Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Cyclacel Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Cyclacel Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Cyclacel Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Cyclacel Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Cyclacel Pharmaceuticals shares will generate the highest return on investment. By understating and applying Cyclacel Pharmaceuticals stock market price indicators, traders can identify Cyclacel Pharmaceuticals position entry and exit signals to maximize returns.
Cyclacel Pharmaceuticals Return and Market Media
The median price of Cyclacel Pharmaceuticals for the period between Mon, Sep 2, 2024 and Sun, Dec 1, 2024 is 0.92 with a coefficient of variation of 36.35. The daily time series for the period is distributed with a sample standard deviation of 0.29, arithmetic mean of 0.8, and mean deviation of 0.25. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Walker Karin L of 2374 shares of Cyclacel Pharmaceuticals at 6.69 subject to Rule 16b-3 | 09/18/2024 |
2 | Cyclacel Pharmaceuticals Now Covered by StockNews.com | 10/02/2024 |
3 | Sangamo Therapeutics, Cyclacel Pharma, GE Aerospace 3 Stocks Retailers Are Most Bullish Tuesday Afternoon - Barchart | 10/22/2024 |
4 | Harmony Biosciences Holdings, Inc. Q3 Earnings and Revenues Surpass Estimates | 10/29/2024 |
5 | Adherex Technologies Inc. Reports Q3 Loss, Misses Revenue Estimates | 11/07/2024 |
6 | Cyclacel Pharmaceuticals Announces Exercise of Warrants for 2.1 Million Gross Proceeds | 11/13/2024 |
7 | Armistice Capital, LLC Increases Stake in Cyclacel Pharmaceuticals Inc | 11/15/2024 |
8 | Cyclacel Pharmaceuticals Reports Q3 2024 Financial Results - TipRanks | 11/18/2024 |
9 | Cyclacel Pharmaceuticals, Inc. Short Interest Up 906.1 percent in November | 11/27/2024 |
About Cyclacel Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Cyclacel or other stocks. Alpha measures the amount that position in Cyclacel Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 (projected) | Dividend Yield | 0.0885 | 0.0929 | Price To Sales Ratio | 6.22 | 5.91 |
Cyclacel Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Cyclacel Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cyclacel Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Cyclacel Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Cyclacel Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Cyclacel Pharmaceuticals' management manipulating its earnings.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Cyclacel Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Cyclacel Pharmaceuticals Backtesting, Cyclacel Pharmaceuticals Valuation, Cyclacel Pharmaceuticals Correlation, Cyclacel Pharmaceuticals Hype Analysis, Cyclacel Pharmaceuticals Volatility, Cyclacel Pharmaceuticals History and analyze Cyclacel Pharmaceuticals Performance. For information on how to trade Cyclacel Stock refer to our How to Trade Cyclacel Stock guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Cyclacel Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.